SLL
Zanubrutinib Improves PFS Over Doublet Treatment for CLL, SLL
Cecilia BrownChronic Lymphocytic Leukemia | February 1, 2023
Zanubrutinib led to significant PFS improvements compared with bendamustine plus rituximab in patients with CLL or SLL.
Read More
Gilead Pulls Idelalisib Indications From US Market After Failing to Confirm Clinical Benefit
Sabrina AhleIndolent B-Cell Lymphoma | November 14, 2022
After failing to complete the requisite confirmatory trials following accelerated approval, Gilead has announced it will ...
Read More
Advertisement
Advertisement
Advertisement

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    Editorial Board

    About Us

    Terms of Use

    Advertising

    Privacy Policy

    Editorial Policy

    Our Network

    MashupMD

    GU Oncology Now

    Cancer Nursing Today

    Urban Health Today

    DocWire News

    Connect

    eNewsletters

    Calendar of Events

    Contact Us

    Contribute

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |